HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock DownZacks Investment Research • 12m
HALO Rallies More Than 40% in 6 Months: How Should You Play the Stock?Zacks Investment Research • Tuesday
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons WhyZacks Investment Research • 11/10/26
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?Zacks Investment Research • 11/10/26
HALO Q3 Earnings Call Highlights Royalty Growth and Patent DisputeZacks Investment Research • 11/06/26
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029PRNewsWire • 11/06/26
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck CancerPRNewsWire • 11/06/26
Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/06/26
Halozyme Therapeutics (HALO) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/05/26
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCEPRNewsWire • 11/05/26
Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 11/04/26
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarZacks Investment Research • 10/30/26
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 10/29/26
How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New HighsInvestors Business Daily • 10/23/26
5 Strong Buy Growth Stocks With High Margins to Grab Before EarningsZacks Investment Research • 10/21/26